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Abstract
The asymmetric Pd-catalyzed decarboxylative allylic alkylation of differentially N-protected 
piperazin-2-ones allows for the synthesis of a variety of highly enantioenriched tertiary 
piperazine-2-ones. Deprotection and reduction affords the corresponding tertiary piperazines, 
which can be employed for the synthesis of medicinally important analogs. The introduction of 
these chiral tertiary piperazines resulted in imatinib analogs that exhibited comparable 
antiproliferative activity to that of their corresponding imatinib counterparts.
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Piperazine is a common structural motif in pharmaceuticals and is considered to be a 
privileged scaffold in medicinal chemistry.[1] Piperazine itself has been used as an 
anthelmintic and notable piperazine-containing small molecule pharmaceuticals include 
imatinib (1), a kinase-inhibiting anticancer agent;[2] ciprofloxacin (2), a potent 
fluoroquinolone antibiotic;[3] piribedil (3), an antiparkinsonian agent;[4] and indinavir (4), an 
HIV protease inhibitor (Figure 1a).[5] Common methods for the selective asymmetric 
preparation of substituted piperazines[6] include enantio selective hydrogenation,[7] enzyme-
mediated chiral resolution,[8] α-lithiation mediated by (−)-sparteine and other chiral 
diamines,[9] Pd-catalyzed cyclizations,[10] or synthesis from amino acids or other members 
of the chiral pool.[11] One of the most straight forward methods for the synthesis of chiral 
piperazines is the reduction of the corresponding chiral keto- or diketopiperazine. However, 
methods for the asymmetric preparation of these piperazine precursors are currently limited.
Piperazin-2-ones possess an additional functionality (i.e. the carbonyl) that allow for the 
synthesis of more highly substituted piperazine-2-ones, which, upon reduction, yield 
substituted piperazine derivatives. Although piperazin-2-ones are employed infrequently in 
medicinal chemistry, they can be found in some pharmaceutical agents including the p53/
MDM2 inhibitor (−)-nutlin-3 (5, Figure 1a),[12] and in several naturally occurring bioactive 
compounds including the marcfortines,[13] pseudotheonamides,[14] and malbrancheamides 
(Figure 1b).[15] Piperazin-2-ones also play a crucial role as conformationally constrained 
peptidomimetics. These piperazin-2-ones mimic inverse γ-turns in peptides, which play 
crucial roles in the secondary structures of proteins.[16] Chiral piperazin-2-ones[17] can be 
prepared from amino acids or other members of the chiral pool[18] or by chiral auxiliary-
mediated alkylations[19] or dynamic resolutions.[20] However, most of the available methods 
are not capable of generating chiral α-tertiary piperazin-2-ones (6, Figure 2) and there are no 
previous examples that prepare this motif by catalytic enantioselective methods. Thus, there 
is an unaddressed absence of catalytic asymmetric synthesis strategies to these valuable 
compounds.
Our research group has had a longstanding interest in the construction of α-tetrasubstituted 
carbonyl compounds including quaternary centers using transition metal catalysis and has 
developed conditions for the asymmetric allylic alkylation of lactams to furnish α-
quaternary lactam products.[21] Morpholin-3-ones were also identified as viable substrates 
under the same conditions, generating an α-tertiary stereo center.[22] We sought to extend 
this catalyst system to enantio selectively generate α-tertiary piperazin-2-ones (6), which, 
upon subsequent reduction, would generate chiral tertiary piperazines (7). α-Tertiary 
piperazine species are not well precedented in the literature presumably due to the 
difficulties associated with their preparation, and no general methods exist for their 
asymmetric synthesis, let alone catalytic asymmetric synthesis. A direct, catalytic 
asymmetric synthesis of tertiary piperazin-2-ones and their subsequent reduction to the 
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piperazines would provide access to an invaluable scaffold, enabling the exploration of 
unprecedented chemical space (Figure 3).
Medicinal chemistry has long utilized linearly substituted, non chiral piperazines and has 
also, although less frequently, utilized chiral α-secondary piperazines, as in indinavir (4).22 
Access to enantiopure α-tertiary piperazines would provide a unique opportunity to explore 
these three dimensionally elaborated piperazines in drug discovery.
Given that secondary and tertiary nitrogen atoms may exhibit undesired reactivity in Pd-
catalyzed reactions, it is necessary to protect both nitrogens of the ketopiperazine ring. 
Taking into consideration our prior results, in which N-benzoyl protected lactams reacted 
with high enantioselectivities in the decarboxylative asymmetric allylic alkylation,[21e] we 
began our studies with the 1,4-bisbenzoylated piperazin-2-one 8a (Table 1). When utilizing 
Pd2 (pmdba)3 [tris(4,4’-methoxydibenzylideneacetone) dipalladium (0)] at 5 mol % catalyst 
loading and the (S)-(CF3)3-t-BuPHOX ligand at 12.5 mol % loading in a 0.014 M solution 
of toluene, the bis-N-benzoylated α-allylated product 9a (Table 1) was formed in high yield 
but modest ee. It was reasoned that the sp2-hybridized nature of the N(4) position was 
detrimental to the enantioselectivity of the reaction due to its ability to stabilize the enolate 
intermediate.[23] Taking into consideration the need for an alkyl protecting group at the N(4) 
position, we next examined 4-benzylpiperazin-2-one 8b (R1=Bz, R2=Bn, R3=Me, R4=H). 
Under our standard conditions, the N-benzyl-protected α-allylated compound 9b was 
obtained in both good yield and ee. Additional N(4)-protecting groups were investigated 
which allow for the chemoselective deprotection of N(4). The para-methoxybenzyl 
protecting group, which can be cleaved by acidic or oxidative conditions, would allow for 
orthogonal deprotection. 4-Methoxybenzylpiperazin-2-one 9c was also obtained in good ee 
but with slightly lower yield than the 4-benzyl compound 9b. Given the slightly higher 
yield, the 4-benzyl protecting group was selected for further optimization.
In efforts to increase the ee of the allylic alkylated products, additional protecting groups at 
the N (1) position were examined. Considering that benzoylated compounds provided the 
best results in the lactam case,[21e] we examined additional acyl protecting groups (Table 1). 
The para-fluoro benzoyl and para-methoxybenzoyl compounds 9d and 9e were obtained in 
nearly identical ee and just slightly lower yields, demonstrating that substantial electronic 
changes of the N(1)-substituent do not have a strong influence on the reaction efficiency or 
selectivity. However, the reaction is somewhat sensitive toward ortho substitution at the 
N(1)-benzoyl group as 9f was obtained in a significantly lower enantiomeric excess 
compared to 9d and 9e. Additionally, the1-carboxybenzyl ketopiperazine 9g was also 
prepared in high yield, albeit moderate ee. Given these data, the unsubstituted benzoyl group 
was selected as the optimal choice of N(1)-protecting group, and the benzyl group was 
selected as the optimal N(4)-group.
With protecting groups for both nitrogen atoms investigated, the scope of the reaction with 
regard to the α-substituent was examined. Piperazin-2-ones bearing alkyl (9h, 9i) and benzyl 
(9j) groups were prepared, as was benzyl ether 9k (Table 1), which provides an additional 
handle for further functionalization. Additionally, bicyclic product 9n, which is reminiscent 
of the marcfortine core, was obtained in good yield in the reaction (Table 1). The effect of 
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expanding ring size was also examined. The 1,4-diazepan-2-one 9o was formed with only 
moderate enantiomeric excess, a result that suggests that the reaction is sensitive to ring size, 
contrary to the lactam examples.[21e]
Common piperazine pharmacophores include N-arylpiperazines and N-methylpiperazines,24 
and we sought to determine if 4-aryl ketopiperazines and 4-methyl ketopiperazines were 
also competent substrates in this chemistry. The low ee observed in bis-benzoylated 
compound 9a suggests that an sp2-hybridized N(4) position would prove detrimental to the 
enantioselectivity of the reaction. Despite this, 4-phenyl compound 9p, with its partial sp2-
nature of its aniline nitrogen, could be obtained in good yield and with excellent 
enantiomeric excess (Table 1). The 4-methylketopiperazine 9q could also be prepared in 
good yield but with slightly diminished ee.
Contrary to results with the piperdinone substrates, we were delighted to find that even the 
unsubstituted α-secondary ketopiperazine 11a could be obtained in excellent yield and 
enantioselectivity (Table 2). Previous attempts to generate trisubstituted stereo centers via 
our asymmetric allylic alkylation of lactam and ketone substrates were unsuccessful. Such 
experiments have generally resulted in mixtures of mono-, di-, and unallylated products, and 
the desired trisubstituted product was formed in poor yield and with only moderate ee. We 
were delighted to find that in the case at hand, unsubstituted α-secondary ketopiperazine 11a 
could be obtained with no detectable amounts of di- or unallylated byproducts. It is likely 
that the low acidity of the α-hydrogen of the monosubstituted piperazin-2-one substrate and 
product is key to obtaining a high yield of the monoallylated product. Given this exciting 
result, additional allyl substrates were tested (Table 2). Numerous allyl groups are 
compatible, including methallyl 11b, chloroallyl 11c, and phenylallyl 11d which were all 
obtained in fair to excellent yield and high enantioselectivity.
The ketopiperazine products can be converted to the related piperazines in two steps, 
hydrolysis of the benzoyl group to piperazine-2-one 12 followed by reduction of the amide 
to piperazine 13 (Scheme 1A). The deprotected N(1) position can be further alkylated to 
form for instance, di-allyl piperazin-2-one 15 (Scheme 1B). Cross-metathesis can also be 
performed (Scheme 1C). Additionally, the 4-methoxybenzylgroupcan be selectively cleaved 
under oxidative conditions to form piperazine-2-one 17 (Scheme 1D).
Finally, we have demonstrated that these tertiary piperazines can successfully be 
incorporated into known piperazine-containing pharmaceuticals, leading to novel analogs 
with comparable bioactivities in preliminary testing. Substitution on the piperazine ring has 
been shown to modulate bioactivity and, in some cases, result in more specific and stronger 
enzyme binding.[25] We considered imatinib (1), an antiproliferative agent developed for the 
treatment of several cancers, notably including Philadelphia chromosome-positive chronic 
myelogenous leukemia (CML),[2] to be an ideal candidate for proof of concept. Imatinib 
targets the Abl tyrosine kinase domain of the Bcr-Abl fusion protein, and it is known that 
genetic point mutations can render imatinib ineffective because it is no longer able to bind to 
the enzyme.[26] The piperazine moiety of the molecule forms two key hydrogen bonds to 
two amino acid residues, and thus plays a crucial role in binding.[27]
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Given that the piperazine is so crucial to the binding of imatinib, we wanted to explore 
whether highly substituted and congested piperazine analogs would disrupt these 
interactions. Enantiomerically pure, benzylated analog 18 (Scheme 2) was assessed for its 
antiproliferative activity against the human K562 CML cell line.
N-substituted analog 18 was found to have significantly less antiproliferative activity than 
imatinib (1, Table 3) signifying that too much bulk around N(4) might perturb key 
interactions. We also synthesized two novel des-methyl tertiary piperazine-containing 
imatinib analogs (Scheme 2). These analogs, (S)-20 and (R)-20, were assayed for their 
antiproliferative activity and were found to have activities slightly greater than that of N-
desmethyl imatinib (CGP 74588) 19, the main bioactive metabolite of imatinib. The (R)-
enantiomer is slightly more potent ((R)-20, Table 3). These results point to the potential 
utility of stereochemically-rich piperazines as important building blocks for medicinal 
chemistry. Additionally, these novel substructures will likely open up new chemical space 
around a privileged scaffold in drug discovery.
In summary, we have developed the first catalytic enantioselective synthesis of α-tertiary 
piperazin-2-ones. These important molecules can be easily converted to novel α-tertiary 
piperazines. This method utilizes palladium catalysts derived from Pd2(pmdba)3 and 
electron-deficient PHOX ligands to deliver α-tertiary piperazin-2-ones in good to excellent 
yields and enantioselectivities. This method also allows for the synthesis of α-secondary 
piperazin-2-ones in modest to excellent yields and good to excellent enantioselectivities. In 
addition to being tolerant of a variety of N-substitutions, this reaction is also tolerant of 
substitution at the stereocenter including fused bicycles such as those found in piperazine-2-
one-containing natural products. We have further demonstrated that these chiral piperazin-2-
ones can be reduced to the corresponding chiral piperazines, and these chiral α-tertiary 
piperazines can successfully be incorporated into known piperazine-containing 
pharmaceuticals. Specifically, these piperazines can be incorporated into the imatinib 
framework without major perturbation of the drug’s antiproliferative activity against the 
human K562 CML cell line, thus indicating the enormous potential that these novel three-
dimensionally elaborated chiral piperazines have in drug discovery.
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A) Representative piperazine and piperazin-2-one containing pharmaceuticals. B) 
Representative bioactive natural products possessing piperazin-2-one core structures.
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α-Tertiary piperazin-2-one and α-tertiary piperazine.
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Entry into largely unexploited chemical space.
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A) Protecting group cleavage and reduction to yield piperazine 13. B) Protecting group 
cleavage and alkylation to yield piperazin-2-one 15. C) Cross-metathesis with ethyl acrylate. 
D) Oxidative cleavage of PMB protecting group.
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Synthesis of imatinib analogs from precursor 19.
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Table 1
Catalytic enantioselective piperazin-2-one decarboxylative allylic alkylation. Scope of protecting group 
tolerance and scope of α-substituents.
[a]Conditions: piperazin-2-one 8 (1.0 equiv), Pd2(pmdba)3 (5 mol %), (S)-(CF3)3-t-BuPHOX (12.5 mol %) in toluene (0.014 M) at 40 °C for 12–
48 h. All reported yields are for isolated products. The ee were determined by chiral SFC.
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Table 2
Scope of allyl substituents for α-secondary piperazin-2-ones.
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Table 3
Antiproliferative activity of imatinib and imatinib analogs
[a]
IC50 values are against K562 CML cells and are reported ± standard deviation
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